Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 227

1.

Drug Class Review: Thiazolidinediones: Final Report Update 1 [Internet].

Norris SL, Carson S, Thakurta S, Chan BKS.

Portland (OR): Oregon Health & Science University; 2008 Aug.

2.

Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.

Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL.

Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006739. doi: 10.1002/14651858.CD006739.pub2. Review.

PMID:
18425967
3.

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.

Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, De Larochellière R, Staniloae CS, Mavromatis K, Saw J, Hu B, Lincoff AM, Tuzcu EM; PERISCOPE Investigators.

JAMA. 2008 Apr 2;299(13):1561-73. doi: 10.1001/jama.299.13.1561. Epub 2008 Mar 31.

PMID:
18378631
4.

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, Viberti G; Diabetes Outcome Progression Trial (ADOPT) Study Group.

Diabetes Care. 2008 May;31(5):845-51. doi: 10.2337/dc07-2270. Epub 2008 Jan 25.

PMID:
18223031
6.

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.

Singh S, Loke YK, Furberg CD.

JAMA. 2007 Sep 12;298(10):1189-95.

PMID:
17848653
7.
8.

Induction of long-term glycemic control in type 2 diabetic patients using pioglitazone and metformin combination.

Panikar V, Joshi SR, Bukkawar A, Nasikkar N, Santwana C.

J Assoc Physicians India. 2007 May;55:333-7.

PMID:
17844692
9.

Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review.

Eurich DT, McAlister FA, Blackburn DF, Majumdar SR, Tsuyuki RT, Varney J, Johnson JA.

BMJ. 2007 Sep 8;335(7618):497. Epub 2007 Aug 30. Review.

10.

The increase in abdominal subcutaneous fat depot is an independent factor to determine the glycemic control after rosiglitazone treatment.

Kim SK, Hur KY, Kim HJ, Shim WS, Ahn CW, Park SW, Cho YW, Lim SK, Lee HC, Cha BS.

Eur J Endocrinol. 2007 Aug;157(2):167-74.

11.

Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus.

Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, Wiley C, Selvin E, Wilson R, Bass EB, Brancati FL.

Ann Intern Med. 2007 Sep 18;147(6):386-99. Epub 2007 Jul 16. Review. Erratum in: Ann Intern Med. 2007 Dec 18;147(12):887.

PMID:
17638715
12.

Rosiglitazone for type 2 diabetes mellitus.

Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH.

Cochrane Database Syst Rev. 2007 Jul 18;(3):CD006063. Review.

PMID:
17636824
13.

Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin.

Derosa G, Fogari E, Cicero AF, D'Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Gravina A, Ferrari I, Fogari R.

Hypertens Res. 2007 May;30(5):387-94.

PMID:
17587750
14.
15.

Peroxisome proliferator-activated receptor gamma agonists for the Prevention of Adverse events following percutaneous coronary Revascularization--results of the PPAR study.

Bhatt DL, Chew DP, Grines C, Mukherjee D, Leesar M, Gilchrist IC, Corbelli JC, Blankenship JC, Eres A, Steinhubl S, Tan WA, Resar JR, AlMahameed A, Abdel-Latif A, Tang WH, Brennan D, McErlean E, Hazen SL, Topol EJ.

Am Heart J. 2007 Jul;154(1):137-43. Erratum in: Am Heart J. 2007 Aug;154(2):402. Tang, H Wilson [corrected to Tang, W H Wilson].

PMID:
17584566
16.

Pioglitazone has anti-inflammatory effects in patients with Type 2 diabetes.

Heliövaara MK, Herz M, Teppo AM, Leinonen E, Ebeling P.

J Endocrinol Invest. 2007 Apr;30(4):292-7.

PMID:
17556865
17.

Coronary heart disease outcomes in patients receiving antidiabetic agents.

McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM.

Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):711-25.

PMID:
17551989
18.

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.

Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Group.

N Engl J Med. 2007 Jul 5;357(1):28-38. Epub 2007 Jun 5.

20.

Thiazolidinediones and heart failure: a teleo-analysis.

Singh S, Loke YK, Furberg CD.

Diabetes Care. 2007 Aug;30(8):2148-53. Epub 2007 May 29.

PMID:
17536074
Items per page

Supplemental Content

Write to the Help Desk